Tianjin Medical University Cancer Institute and Hospital: Neoplasms trials

The registry lists 11 Neoplasms studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 3No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid TumorsNot yet recruitingNCT07866534Not applicable
• A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）Not yet recruitingNCT07496073Phase 1
• A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid TumorRecruitingNCT06954558Phase 1
• A Clinical Study of CHT101 in CD70-Positive Advanced Solid TumorsRecruitingNCT06730659Phase 1
• A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid TumorsRecruitingNCT06717022Not applicable
• Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast CancerRecruitingNCT06495515Phase 2
• TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant TumorsRecruitingNCT06487663Not applicable
• Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.Status unknownNCT05036798Phase 2
• A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical ConizationStatus unknownNCT03745846Phase 2
• PERCIST Criteria for Response Evaluation With Solid TumorsStatus unknownNCT02765620
• Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant TumorsStatus unknownNCT01694472Phase 1